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Abstract. The use of liposomal nanoparticles with an incorporated active substance is an innovative and 
promising approach to diagnostics and therapy. The application of liposomal nanoparticle-based drugs 
allows for targeted localized delivery, overcomes the natural barriers within the body effectively, and 
minimizes possible side effects. Liposomes are able to contain a variety of ingredients with practically no 
limitations to their chemical composition, chemical properties, or size of constituent molecules. This study 
evaluated the ability to control the passage of fluorescent dye-filled liposomes through the intestinal 
mucosal barrier after oral administration. For this purpose, the increase in transcutaneous registered 
fluorescence from tetrabromofluorescein dye was recorded and analysed. Fluorescence intensity was 
measured at the proximal end of the tail of an animal model after oral administration of the liposomes. 
Measurements were taken at the excitation wavelengths of 365 and 450 nm. The fluorescence intensity in 
the group treated with the fluorescent contrast agent encapsulated in liposomal particles increased 140% of 
the initial level, but in the group treated with pure contrast agent, the increase in detected fluorescence 
intensity did not exceed 110%. Mice that received empty liposomes as well as the control group did not 
demonstrate statistically significant changes in fluorescence intensity. A potential application of our results 
is an express laser optical method of monitoring the transport of orally administered liposomal particles. 
The results can be used to help create new optical tools for use in the development of new drugs and in 
high-throughput screening used during their testing.  
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1. Introduction 
 
Currently, non-invasive methods of optical diagnostics based on the principles of spectrophotometry and 
fluorescence analysis are widely used in medicine, pharmacology, biology, and chemistry. Optical 
diagnostics and photonics-based techniques are of particular interest in the development of new drugs 
because of their low cost, versatility, and high sensitivity [1]. The development and testing of a new drug 
include the study of its metabonomics, which requires a combination of high sensitivity, operability, and 
ease of automation [2]. Thus, the development of rapid methods of monitoring various biomedical and 
biotechnological processes is of interest. Optical coherence tomography (OCT) has been used effectively 
for assessing the efficiency of transcutaneous vaccine delivery [3-5]. In some cases, near-infrared 
spectroscopy (NIRS) can be used to assess the kinetics of drug release. Furthermore, NIRS and Raman 
spectroscopy can be used to obtain one spectrum that provides universal and multidimensional information 
about the drug, including its physical, chemical, and quantitative properties [6]. In addition, optical imaging 
instruments are being used successfully for the study of drug delivery. Intravital microscopy (IVM) allows 
non-invasive continuous monitoring of drug movement in the body [7]. Photoacoustic (PA) imaging is used 
for the simulation of drug transport and the evaluation of the accumulation of substances in an organ or 
tumour tissue, which is especially important during photodynamic therapy (PDT) [8]. However, these 
methods have several disadvantages that prevent their widespread use in the biotechnological processes of 
the pharmaceutical industry. Some disadvantages include difficulty with performing the procedure, the long 
duration of the measurements, the need for a highly skilled technician to run the equipment, and the high 
cost of equipment. Laser fluorescence spectroscopy (LFS), used in biophotonics, is devoid of many of these 
disadvantages and can sufficiently automate measurements on a large number of objects of research. 
 
LFS has considerable potential in drug discovery, not only during the development of a new drug formula 
but also in preclinical and clinical trials. Nanocontainers are increasingly used to deliver a new generation 
of dosage forms [9,10]. One type of nanoscale drug delivery system is the liposome [11], an artificial 
spherical particle with one or more layers of bimolecular phospholipid [12,13]. The particles have various 
applications, e.g., they can be used to transport and deliver substances to the target mucosa or skin [14,15]. 
Use of liposomal nanoparticles is especially attractive because of the possibility of their administration via 
the oral route, which delivers the content of the nanoparticles directly into the bloodstream [16]. 
 
Many drugs are prone to degradation in the environment of the gastrointestinal tract. In addition, the 
mucosal layer of the small intestine prevents the penetration of many drugs into the bloodstream. High 
viscosity and mucosal adhesion together with an abundance of auxiliary substances can seriously slow 
down the spread of the drug through the mucosal layer. This layer is 100-800 µm thick and comprises a 
complex of highly branched glycoproteins, lipids, cellular and serum macromolecules, and other cellular 
debris [17]. However, the medicament may pass through the gastrointestinal tract with the use of a modified 
liposome. Studies of intestinal permeability have shown that lipid-based particles can be absorbed if their 
diameter is not significantly greater than 500 nm [16]. The transport properties of the liposomal particles 
can be manipulated by adding a polymer coating to the surface. These coatings can resist degradation in 
the hostile environment of the gastrointestinal tract, which includes the salts of bile acids and enzymes. For 
instance, pancreatic lipase typically dissolves the unprotected lipid bilayer [18-20]. A coat of polystyrene 
polymers or poly(ethylene glycol) (PEG) allows the liposomal particles to penetrate the intestinal mucus 
[19]. This was, for the first time, confirmed by one research group (Gifu Pharmaceutical University, Japan) 
that studied the use of orally administered liposomes for targeted delivery of chemotherapeutic agents for 
intestinal cancer [20,21]. This ability to penetrate provides the possibility for unique solutions to certain 
medical problems, because of the perfect biocompatibility of liposomes as carriers of drugs. In addition, 
liposomes can contain radioactive, radiopaque, or paramagnetic substances, and substances that reflect 
ultrasound to improve the quality of images obtained by diagnostic methods such as computed tomography, 
X-ray, ultrasound, and scintigraphy. 
 
The need to monitor the effectiveness of the penetration of drug carriers must be kept in mind during the 
development of targeted drug delivery. The penetration of drugs is monitored in preclinical testing by using 
invasive methods on blood and the tissues of interest in animal models [22,23]. Because these methods are 
time-consuming and difficult to perform, fluorescence spectroscopy may be an alternative method for 
assessing the pharmacokinetic processes of liposomal drug penetration. The main purpose of this study was 
to examine the possibility of using this optical method to control the transport of fluorescent coloured 
liposomal nanoparticles after oral administration in animal models.  
 
2. Experimental method and equipment 
 
A fluorescence channel with a fibre optics probe in series with the multifunctional laser-based non-invasive 
diagnostic laser system “LAKK-M” (SPE “LAZMA” Ltd, Moscow, Russia) was used to perform 
fluorescence spectroscopy (Fig. 1) [24,25]. The system provides multiwavelength excitation, detects 
emission, and processes the fluorescence signal. Its light sources include an LED M365F1 (Thorlabs, Inc., 
Newton, NJ, USA) (wavelength = 365 nm, power = 1.5 mW) and the quantum dot (QD) semiconductor 
laser LP450-SF15 (Thorlabs) (wavelength = 450 nm, power = 3.5 mW), which has high efficiency and low 
relative intensity noise. The above-mentioned fluorescence excitation powers are provided at the tip of fibre 
probe, which induces an excitation light flux in the tissue of no more than 0.16 W/m2 for 365 nm and 
0.37 W/m2 for 450 nm. The spectrometer was a polychromator with a diffraction grating, and a CCD line 
(TCD1304AP, Toshiba, Tokyo, Japan) was used as the detector.  
 
The measurement system was previously used to study tissue metabolism by recording the fluorescence of 
different skin biomarkers [26]. Those studies observed that in probing biological tissue with UV light (e.g., 
365 nm), the maximum of fluorescence emission of endogenous nicotinamide adenine dinucleotide 
(NADH) was in the 450-470-nm wavelength range [27]. When excited with blue light (e.g., 430-450 nm), 
the fluorescence peak of flavins was in the range of about 510-520 nm [28]. Thus, the probing depth of this 
system is sufficient for transcutaneous measurements in animal models. 
 
 
(a) (b) 
 
Figure 1. Schematic representation of the setup used to study the transport of fluorescent coloured 
liposomal nanoparticles in mice using the “LAKK-M” laser system: a) overall view of the experimental 
setup; b) fibre optic probe.  
 
The experimental studies complied with EU Directive 2010/63/EU, which defines a humane attitude 
towards animals and refers to the Three Rs principles (replacement, reduction, and refinement). All studies 
were approved by the Ethical Committee of Orel State University. The model animals were clinically 
healthy mice of outbred stock CD-1 that were divided into four groups using the analogue method. Outside 
of the experiment, the animals were fed the same food. The first group (n = 5) was the control group and 
did not receive any drugs during the experiment. The second group (n = 5) received liposomes without dye, 
the third group (n = 5) received pure dye without liposomes, and the fourth group (n = 5) received 
liposomes with incorporated fluorescent dye. The concentration of eosin-Y in the diet of groups 3 and 4 
was 5 mg/kg body weight. 
 
The fluorescence measurements were made on the proximal end of the tail. The area of skin under study 
was degreased with 96% ethanol solution before each measurement. The fibre optic probe for measuring 
fluorescence was placed normal to the surface of the tail. To reduce photobleaching, the tissue was exposed 
to optical radiation no more than 2 s per measurement. Before administration of the drug, the background 
fluorescence at the two excitation wavelengths of 365 and 450 nm was measured. Fluorescence spectra at 
those wavelengths were recorded at the time of administration and every 15 min over 2 h. 
 
Liposomes were prepared using a modified version of the reverse-phase evaporation method [29]. 
Phospholipids, cholesterol, and PEG were dissolved in chloroform. A rotary evaporator was used to remove 
the organic solvent under vacuum with the water bath at 40 °C and the rotor speed at 100 rpm. Evaporation 
was stopped after formation of a thin lipid film, which then underwent ultrasound sonication for hydration. 
The ultrasound treatment continued until the film was flushed and the liposomes formed were less than 500 
nm in diameter. The fluorescent dye eosin-Y (the disodium salt of 2,4,5,7-tetrabromofluorescein), with a 
maximum intrinsic fluorescence in the 520 ± 5-nm region [30-32], was encapsulated inside the liposomes 
via passive inclusion during lipid film hydration (Fig. 2). 
 
 
 
Figure 2. Structure of a liposomal nanoparticle, which was composed of one layer of bimolecular 
phospholipid that encapsulated the fluorescent dye eosin-Y.  
 
For empty liposomes without the encapsulated dye, the lipid film was hydrated with the sterile saline. 
Unused eosin-Y was removed from the liposome suspension using dialysis against saline. 
 
3. Results and discussion 
 
The main endogenous fluorescent components of mouse skin are collagen and elastin as well as (to a lesser 
degree) NADH, flavin adenine dinucleotide (FAD), porphyrins, and lipofuscin. Most of these substances 
fluoresce at 365 and 450 nm, whereas eosin-Y and fluorescein weakly absorb 365 nm and strongly absorb 
and fluoresce at 450 nm. Measurements obtained using excitation wavelength 365 nm did not show a 
statistically significant difference in fluorescence intensity for all four groups, probably because of the low 
penetration of the UV excitation signal through the skin where the probe was placed and the low extinction 
of the dye at that wavelength. The smoothed and averaged spectra for the 450-nm excitation wavelength 
obtained at the same time (before feeding and 30, 60, and 90 min after feeding) for each group are presented 
in Figure 3. The spectra show a statistically significant increase in fluorescence intensity in the 480-700-
nm wavelength range in the group of mice that received liposomes with encapsulated fluorescent dye. In 
that group, a pronounced increase (140% of the initial level) in the average peak fluorescence intensity 
from 260 ± 39 to 420 ± 36 a.u. 30 min after liposome administration was observed (Fig. 3c). This increase 
in fluorescence intensity was much greater than that for the group of mice treated with pure dye, i.e., from 
283 ± 42 to 351 ± 23 a.u. (which does not exceed 110% of the initial level) at the same time points (Fig. 
3d). Mice that received empty liposomes and the control group did not demonstrate statistically significant 
changes in fluorescent intensity (Figs. 3a and 3b). Table 1 presents the averaged values of the fluorescence 
spectra maxima for the four groups of mice at seven measurement times. 
 
Table 1. Fluorescence intensity maxima of the four groups of mice 
 Fluorescence intensity (a.u.) 
Time (min) Control group Group received liposomes 
Group received 
liposomes with 
incorporated 
fluorescent dye 
Group received 
pure fluorescent 
dye 
0 259 ± 53 286 ± 41 260 ± 39 283 ± 42 
15 261 ± 31 286 ± 53 282 ± 39 298 ± 25 
30 250 ± 41 287 ± 31 420 ± 36 351 ± 23 
45 251 ± 19 307 ± 41 360 ± 31 333 ± 39 
60 258 ± 21 290 ± 19 275 ± 22 325 ± 44 
75 252 ± 41 259 ± 21 290 ± 42 270 ± 25 
90 249 ± 41 251 ± 41 289 ± 42 260 ± 41 
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Figure 3. Fluorescence spectra for 450-nm excitation wavelength (smoothed and averaged for the same 
time frame for each group): (a) control group; (b) group that received empty liposomes; (c) group that 
received liposomes with incorporated fluorescent dye; (d) group that received pure fluorescent dye. 
 
The variation in the fluorescence signal as a function of time is presented in Figure 4.  
 
 
  
       (a)         (b) 
 
Figure 4. Fluorescence as a function of time: (a) control group and group that received empty liposomes; 
(b) group that received liposomes with incorporated fluorescent dye and group that received fluorescent 
dye. 
 
The PEG coating on the lipid layer allowed the liposomal particles to penetrate the intestinal mucus layer. 
The results of our experiments show that the multilayer liposomal particles may increase the effectiveness 
of the transport of the fluorescent dye into the bloodstream via the gastrointestinal tract after oral 
administration. In addition, some fluorescent dye reached the bloodstream through the intestinal mucosa 
without the assistance of the particles and specifically increased the fluorescence intensity (Figs. 3d and 
4b). 
 
According to Sercombe et al. [23], PEG greatly affects the pharmacokinetics of liposomes by increasing 
the circulation time in the blood from 2 to 24 h in rodents (mice and rats) and more than 45 h in humans. 
Circulation time depends of the particle size and the characteristics of the polymer coating. However, this 
prolongation was not observed in this study. The fluorescence intensity returned to the base level 60-90 
min after oral administration. 
 
4. Conclusion 
 
We used LFS to investigate the effectiveness of penetration of fluorescently stained liposomes into the 
circulatory system when administered orally. There was an increase in the fluorescence intensity from 
260 ± 39 a.u. before administration to 420 ± 36 a.u. 30 min after oral administration of the fluorescent 
contrast agent encapsulated in liposomal particles. For the group that was administered pure dye, the 
fluorescence intensity increased slightly from 283 ± 42 to 351 ± 23 a.u. 30 min after administration. The 
possibility of in vivo and in situ express laser optical methods to control the transcutaneous penetration and 
distribution of liposomal forms designed for oral administration was confirmed. Thus, in addition to the 
already wide use of LFS, it has the potential for use in a new application. Our results show that it can be 
used for transcutaneous in vivo measurements and controlled drug administration. Instead of time-
consuming histological analysis of tissue, the LFS approach enables non-invasive measurements and long-
term studies on the same animal, which could accelerate the process of drug discovery. The use of LFS can 
also increase the statistical significance and reliability of clinical trials and reduce the number of animals 
needed and their suffering. The data obtained by this method can provide information about the 
pharmacodynamics and the optimal dosage of the drug. The results can then be used for the development 
of new drugs for transcutaneous delivery and in the high-throughput screening that occurs during testing.  
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